SignatureFD
ALLO icon

SignatureFD’s Allogene Therapeutics ALLO Stock Holding History

SignatureFD’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11K Sell
6,904
-153
-2% -$291 ﹤0.01% 2683
2026
Q2 		$14.7K Sell
7,057
-1,793
-20% -$3.94K ﹤0.01% 2486
2026
Q1 		$21.6K Buy
8,850
+4,795
+118% +$9.6K ﹤0.01% 2161
2025
Q4 		$5.56K Sell
4,055
-301
-7% -$397 ﹤0.01% 2651
2025
Q3 		$5.4K Buy
4,356
+2,803
+180% +$3.34K ﹤0.01% 2638
2025
Q2 		$1.76K Sell
1,553
-5,837
-79% -$7.76K ﹤0.01% 2901
2025
Q1 		$10.8K Buy
7,390
+5,304
+254% +$10K ﹤0.01% 2323
2024
Q4 		$4.44K Sell
2,086
-115
-5% -$284 ﹤0.01% 2646
2024
Q3 		$6.16K Buy
2,201
+1,600
+266% +$4.26K ﹤0.01% 2510
2024
Q2 		$1.4K Sell
601
-3,657
-86% -$10.8K ﹤0.01% 2834
2024
Q1 		$19K Buy
4,258
+106
+3% +$442 ﹤0.01% 2020
2023
Q4 		$13.3K Sell
4,152
-1,798
-30% -$5.1K ﹤0.01% 2126
2023
Q3 		$18.9K Buy
5,950
+2,040
+52% +$8.94K ﹤0.01% 1878
2023
Q2 		$19.4K Buy
3,910
+525
+16% +$2.84K ﹤0.01% 1906
2023
Q1 		$16.7K Buy
3,385
+2,817
+496% +$18.1K ﹤0.01% 1961
2022
Q4 		$3.57K Sell
568
-2,001
-78% -$18.5K ﹤0.01% 2605
2022
Q3 		$28K Hold
2,569
– – ﹤0.01% 1572
2022
Q2 		$29K Buy
2,569
+1,709
+199% +$15.2K ﹤0.01% 1573
2022
Q1 		$8K Buy
860
+831
+2,866% +$8.66K ﹤0.01% 2240
2021
Q4 		$0 Sell
29
-71
-71% -$1.25K ﹤0.01% 3093
2021
Q3 		$3K Buy
100
+70
+233% +$1.66K ﹤0.01% 2496
2021
Q2 		$1K Buy
30
+3
+11% +$86 ﹤0.01% 2668
2021
Q1 		$1K Buy
+27
New +$911 ﹤0.01% 2582
2020
Q4 		– Sell
-42
Closed -$2K – 2540
2020
Q3 		$2K Buy
+42
New +$1.58K ﹤0.01% 2164
2020
Q2 		– Sell
-132
Closed -$3K – 2479
2020
Q1 		$3K Buy
+132
New +$3.14K ﹤0.01% 1784

Other funds holding ALLO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wildcat Capital Management
Wildcat Capital Management New York $174M AUM 46.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

SignatureFD's ALLO Position: Q3 2026 in Review

SignatureFD reduced its Allogene Therapeutics (ALLO) stake by 2.2% in Q3 2026, selling an estimated $291 and leaving 6,904 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

SignatureFD first reported a position in ALLO in Q1 2020 and has held it in 25 quarters since. The position peaked at $29K in Q2 2022. 70 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • SignatureFD held 6,904 shares of Allogene Therapeutics worth $11K as of Q3 2026.
  • SignatureFD sold 153 Allogene Therapeutics shares in Q3 2026, an estimated $291.
  • Allogene Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2683 holding.
  • SignatureFD first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • SignatureFD's Allogene Therapeutics position peaked at $29K in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.